Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

By afschroeder • February 17, 2026

Oshima A, Serruys PW, Garg S, McEvoy JW, Wood DA, Doenst T, Taggart DP, Puskas JD, Shajahan A, Sharif F, Miyashita K, Tobe A, Tsai TY, Revaiah PC, Dunne F, Mehran R, Budoff MJ, Kastelein JJ, Stroes ESG, Khamis R, Koenig W, Onuma Y. Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation. EuroIntervention. 2026 Feb 16;22(4):202-223. doi: 10.4244/EIJ-D-25-00598. PMID: 41697657.

Tags: Cardiology/Epi, Harbor UCLA, Publications

Genetic Reassessment Reveals Catecholaminergic Polymorphic Ventricular Tachycardia in Sisters Initially Diagnosed With Long QT Syndrome

Zhang C, Sarkar A, Wong E, Vaseghi M, Wang JJ. Genetic Reassessment Reveals Catecholaminergic Polymorphic Ventricular Tachycardia in Sisters Initially Diagnosed With Long QT Syndrome.[...]

Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis

Repetti GG, Abel ED, Tontonoz P, Sallam T. Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis. Circ Res.[...]

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool

Jeanjean P, Swaidan A, Tse C, Kwock S, Fajnorova I, Dove R, Azrour IC, Taylor S, Comin-Anduix B, Nathanson DA, Carlucci G, Calais J, Czernin[...]